SYBLEU INC. intends to engage in the primarily in the acquisition, licensing, and development of regenerative medical applications. It develops medical applications up to the point of completion of Phase I and or Phase II clinical trials after which the company sell or license developed applications or advance the application to Phase III clinical trials. SYBLEU INC. was incorporated in 2020 and is based in Bronx, New York. As of April 15, 2024, Sybleu Inc. operates as a subsidiary of Worldwide Holdings, LLC.